Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

Cyclin/CDK inhibition in cancer therapy: from small molecules and macrocycles to advanced drug delivery systems

Cyclin-CDK complexes have attracted growing interest as therapeutic targets due to their crucial role in cell cycle regulation and their application in cancer treatment. Moreover, although CDKs were considered downstream effectors of the DNA damage response (DDR), several evidenc...

Prognostic Role of Adverse Events in a Worldwide Population of Patients with Biliary Tract Cancer Treated with Chemo-Immunotherapy

Background: Biliary tract cancers (BTCs) are aggressive malignancies with limited treatment options. The addition of durvalumab or pembrolizumab to cisplatin–gemcitabine improves overall survival (OS), but validated biomarkers of benefit remain limited. Immune-mediated adverse ev...

First-Line Immune Checkpoint Inhibitors in Older Patients with Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis

Urothelial carcinoma predominantly affects older patients, who often exhibit frailty, comorbidities, renal impairment, and reduced physiological reserve. We evaluated overall survival (OS) and progression-free survival (PFS) with first-line immune-based strategies in patients age...

Electrochemical detection of gallic acid in commercial beverages empowered by the use of paper-based tool to collect and analyze

A simple and innovative paper-assisted electrochemical approach was developed for the determination and temporal monitoring of gallic acid in commercial beverages. The proposed platform combines low-cost screen-printed electrodes with wax-patterned paper discs, enabling the paper...

Cemiplimab in cutaneous squamous cell carcinoma: a longer follow‐up study focusing on the late toxicities

Summary Background and Objectives Cemiplimab was the first systemic therapy approved for advanced cutaneous squamous cell carcinoma (cSCC). Patients and Methods We report findings from the Italian early access program cohort, comprising 134 patients treated with cemiplimab, with...

PIK3CA in Cancer: Structure, Biology, Alterations, and Actionability

PIK3CA, which encodes the p110α catalytic subunit of phosphoinositide 3-kinase (PI3K), is one of the most frequently altered oncogenes in human cancer and a major driver of tumor initiation, progression, metastasis, and therapeutic resistance. Over the past two decades, advances...

Development and Internal Validation of a Clinical Risk Score for Hypovitaminosis D in Italian Adults Aged ≥50 Years Attending Osteoporosis and Metabolic Bone Disease Centers

Background/Objectives: Hypovitaminosis-D is a highly prevalent condition worldwide, associated with adverse skeletal and extra-skeletal outcomes. Increasing demand for serum 25-hydroxyvitamin D (25(OH)D) testing points toward the need for simple tools to identify individuals at r...

The New Cardio-Oncology Frontier in Hematologic Cancers: Cardiovascular Toxicities of CAR-T Cells and Bispecific T-Cell Engagers

Chimeric antigen receptor T-cell therapy and bispecific T-cell engagers have transformed treatment of relapsed and refractory hematologic malignancies, achieving unprecedented response rates. However, their clinical adoption has revealed a complex spectrum of cardiovascular toxic...

Global Real‐World Outcomes of Olaparib in Metastatic Castration‐Resistant Prostate Cancer Patients With Homologous Recombination Repair Alterations

Evidence to guide the treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) and Homologous Recombination Repair (HRR) gene alterations outside of clinical trials remains limited. This was an observational, cohort study, including mCRPC patients with...